BioLamina AB
PrivateLast Round
Debt
Apr 17, 2026
Total Funding Raised
$23.59M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BioLamina AB operates in Healthcare & Life Sciences and is based in Sundbyberg. Its latest recorded funding round was a Debt round in April 2026.
BioLamina AB is a biotechnology company that develops, manufactures, and commercializes human recombinant laminin substrates for cell culture research and therapeutic applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioLamina AB Comparables
Compare BioLamina AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nucleus Biologics | 86% | |
| STEMCELL Technologies | 82% | |
| MATRIXOME, Inc. | 81% |
For institutional investors. Book with your work email.
BioLamina AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Apr 17, 2026 | ||||
| VC Round | Sep 12, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioLamina AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lauxera Capital Partners | VC Round |
| European Investment Bank Group | Debt |
| Northislet AB | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 91% MoM, reaching 34.7K.
- Apr 16, 2026
Monthly visitors increased 41% MoM, from 9.1K to 12.9K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withAug 19, 2026
On Aug 19th '26, BioLamina AB and Axion BioSystems partner to advance organoid research for disease modeling and therapeutic discovery, with BioLamina AB's LN332 incorporated into Axion BioSystems's offering to improve neural and cardiac organoid attachment to multielectrode array plates.
For institutional investors. Book with your work email.
BioLamina AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioLamina AB's valuation, stock price, and market status.
Is BioLamina AB a public or private company?
BioLamina AB is a private company.
What is the current stock price of BioLamina AB?
BioLamina AB is a private company, so its shares have no public market price. Caplight tracks BioLamina AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioLamina AB worth (valuation)?
Valuation information for BioLamina AB is not publicly available.
Can I buy BioLamina AB stock?
BioLamina AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioLamina AB's last funding round?
BioLamina AB's most recent funding round was Debt on April 17, 2026.
Who are the main investors in BioLamina AB?
Key investors in BioLamina AB include Lauxera Capital Partners.
Will BioLamina AB IPO soon?
No public IPO plans have been announced for BioLamina AB.
How can I track BioLamina AB secondary market activity?
Caplight tracks bids, offers, and trades in BioLamina AB's shares on secondary markets.